Asia Pacific Cell Therapy Market Size & Outlook, 2023-2030
Asia Pacific cell therapy market, 2018-2030 (US$M)
Related Markets
Asia Pacific cell therapy market highlights
- The Asia Pacific cell therapy market generated a revenue of USD 667.9 million in 2023.
- The market is expected to grow at a CAGR of 22.6% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Autologous Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 667.9 million |
| Market revenue in 2030 | USD 2,774.9 million |
| Growth rate | 22.6% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Autologous Therapies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Allogeneic Therapies, Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 14.1% of the global cell therapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 6,066.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Therapy Market Scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 76.34% in 2023. Horizon Databook has segmented the Asia Pacific cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Cell Therapy Therapy Type Outlook (Revenue, USD Million, 2018-2030)
- Allogeneic Therapies
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
- Stem Cell Therapies
- Autologous Therapies
- Stem Cell Therapies
- BM, Blood, & Umbilical Cord-derived Stem Cells
- Adipose Derived Cells
- Others
- Non-stem Cell Therapies
- T-Cell Therapies
- CAR T Cell Therapy
- T Cell Receptor (TCR)-based
- Others
- T-Cell Therapies
- Stem Cell Therapies
- Allogeneic Therapies
- Asia Pacific Cell Therapy Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Reasons to subscribe to Asia Pacific cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific cell therapy market databook
-
Our clientele includes a mix of cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cell therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific cell therapy market size, by country, 2018-2030 (US$M)
Asia Pacific Cell Therapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
